Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Integer Holdings - The lawsuit alleges that Integer Holdings made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is claimed that Integer overstated its visibility into customer demand while experiencing a decline in sales for two of its electrophysiology devices [5]. - The lawsuit asserts that Integer mischaracterized its electrophysiology devices as long-term growth drivers for its cardio and vascular segment, leading to misleading positive statements about its business and operations [5].

Core Viewpoint - VEON Ltd. has launched the "Invest in Pakistan, NOW!" initiative in partnership with JazzWorld to attract international investors to Pakistan as the country's economic fundamentals improve and growth opportunities become more apparent [1][5][6] Group 1: Initiative Details - The initiative aims to encourage international investors to reconsider Pakistan, highlighting the strengthening economic fundamentals and long-term growth prospects [1][5] - JazzWorld and Nutshell Group of Pakistan signed a Memorandum of Understanding (MoU) to foster dialogue and partnerships focused on digitalization and cross-border investment [2][5] - The signing ceremony was attended by key figures including the Minister of State for Finance and Railways of Pakistan and senior executives from VEON and JazzWorld [3][5] Group 2: Economic Context - The Minister of State for Finance emphasized that Pakistan has achieved macroeconomic stability, supported by government initiatives to enhance investor confidence and the business environment [5] - VEON Group CEO noted that the region is on the verge of a significant transformation, driven by AI and human-centered innovation, which can enhance growth and improve lives [6] Group 3: VEON's Commitment - VEON has invested over USD 11 billion in Pakistan since its establishment in 1994, demonstrating its long-term commitment to the market [8] - The company operates JazzWorld, which serves 100 million customers and offers a wide range of digital services, including connectivity, fintech, and entertainment [7][10] Group 4: Future Outlook - Aamir Ibrahim, CEO of JazzWorld, highlighted that Pakistan's long-term fundamentals are strong, and the country is well-positioned for growth, making it an attractive opportunity for regional and global investors [6][7]

Core Insights - Doha Design District (DDD) and Virginia Commonwealth University School of the Arts in Qatar (VCUarts Qatar) have formed a partnership to enhance the creative and cultural landscape in Qatar [1] Group 1: Partnership Details - The collaboration aims to foster innovation and creativity within the design and arts sectors in Qatar [1] - DDD will serve as a hub for creative industries, providing resources and support for artists and designers [1] Group 2: Impact on the Industry - This partnership is expected to attract local and international talent, contributing to the growth of Qatar's creative economy [1] - The initiative aligns with Qatar's vision to diversify its economy and promote cultural development [1]

Core Insights - Msheireb Downtown Doha has successfully concluded its winter season, attracting 5 million visits from November 2025 to early February 2026, establishing itself as a premier destination for both residents and tourists in the GCC region [1][2] Group 1: Visitor Engagement and Experience - The district's hotels achieved occupancy rates above 95% during November, December, and January, reflecting a significant year-on-year increase from 2024 to 2025, driven by a mix of GCC guests and international visitors [2] - The winter season featured a variety of activities, including sports, art, and cultural events, aimed at creating a people-centric urban environment that celebrates local identity [3] - Key attractions included the Baraha Premium Fan Zone and Sikkat Wadi Msheireb, which hosted live screenings and interactive activities during the Arab Cup 2025 [4] Group 2: Family and Community Activities - Families enjoyed the second year of Sweet Sikka at Sahat Al Nakheel, featuring interactive games, while Barahat Msheireb hosted the fourth edition of Baraha Cinema with outdoor screenings [5] - National celebrations for Qatar National Day included interactive installations and live performances, enhancing community engagement [6] - Msheireb Museums welcomed over 70,000 visitors, showcasing exhibitions and educational workshops, further promoting cultural engagement [7] Group 3: Unique Offerings and Events - Hosh Msheireb provided a boutique glamping experience, featuring cabanas and storytelling activities, appealing to families seeking a cozy escape [8] - The winter season concluded with Art Basel Qatar, marking the fair's first edition in the MENASA region, featuring 87 international exhibitors and 84 artists, bridging regional tradition with contemporary art [9][10]

If you purchased or acquired Fermi: (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s October 2025 initial public offering (“IPO” or the “Offering”); and/or (b) securities between October 1, 2025 and December 11, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate i ...

Core Viewpoint - Rosen Law Firm is reminding sellers of Endeavor Group Holdings, Inc. Class A common stock about a lead plaintiff deadline for a class action lawsuit related to alleged misleading statements and omissions during a specified class period [1][5]. Group 1: Class Action Details - The class period for the lawsuit is defined as between January 15, 2025, and March 24, 2025 [1]. - Investors who sold Endeavor Class A common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 18, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been recognized as a leader in the field [4]. Group 3: Allegations Against Endeavor - The lawsuit seeks to recover damages for investors due to allegedly false and misleading statements in Endeavor's January 15, 2025 Information Statement and related SEC filings [5]. - Specific allegations include misleading information regarding the true value of Endeavor's shares and failure to disclose executive earnings and conflicts of interest related to a take-private merger [5].

Core Insights - The presentation by Jim Rickards highlights the intersection of federal authority, domestic production initiatives, and leadership changes as the U.S. approaches its 250th anniversary, shaping the economic direction of the country [1][3][12] Federal Authority and Legislation - Public Law 63-43 is identified as a significant legal framework that grants the President authority to act on national priorities and economic planning [2] Domestic Industry and Economic Stability - Emphasis is placed on the importance of domestic industry for long-term economic stability, with industrial growth reliant on access to reliable energy sources and critical materials [5] - Recent federal programs aim to accelerate project development and remove barriers to infrastructure and resource production, reinforcing industrial capabilities and supporting economic independence [6] Monetary Leadership and Economic Conditions - Changes in leadership at the Federal Reserve are expected to influence economic conditions, particularly regarding borrowing costs, which affect business activity and infrastructure expansion [7] - The current Federal Reserve Chair's term is set to conclude in May 2026, allowing the President to appoint new leadership, which may align with policies promoting domestic growth and industrial expansion [8] Resource Development and National Policy - The presentation underscores the growing importance of resource development in national policy, with a focus on reducing reliance on foreign sources for essential materials [9][10] - This approach is part of a long-term strategy to enhance national resilience and production capacity [10] Historical Context of Economic Policy - Current policy activities are placed within a broader historical context, suggesting that significant shifts in economic direction often occur when legal authority, industrial planning, and monetary conditions align during pivotal national moments [11]

Washington, D.C., Feb. 07, 2026 (GLOBE NEWSWIRE) -- As satellite-based internet systems continue to scale at a rapid pace, a new video presentation hosted by technology analyst James Altucher examines why he believes March 26, 2026 is beginning to stand out as a meaningful date in the evolution of global communications. Rather than framing the discussion around speculation, the presentation focuses on observable developments tied to Starlink, the space-based internet network overseen by Elon Musk, and how t ...

Core Insights - Roche announced that fenebrutinib, an investigational BTK inhibitor, met its primary endpoint of non-inferiority compared to OCREVUS in reducing disability progression in patients with primary progressive multiple sclerosis (PPMS), showing a 12% reduction in risk [1][5][6] Group 1: Study Results - The Phase III FENtrepid study involved 985 adult patients with PPMS, comparing daily oral fenebrutinib to intravenous OCREVUS for at least 120 weeks [7][12] - Fenebrutinib demonstrated a consistent treatment effect on the composite confirmed disability progression (cCDP12) across various patient subgroups, with curves separating as early as 24 weeks [1][2] - A post-hoc analysis indicated fenebrutinib was superior to OCREVUS on a composite endpoint, showing a 22% reduction in risk [3] Group 2: Treatment Effects - The strongest treatment effect was observed on the nine-hole peg test (9HPT), with a 26% reduction in the risk of worsening compared to OCREVUS [2] - Fenebrutinib showed a consistent clinical benefit in upper limb function, which is crucial for maintaining independence [3] Group 3: Safety Profile - Adverse events in the fenebrutinib group were comparable to OCREVUS, with infections occurring in 67.0% of patients on fenebrutinib versus 70.9% on OCREVUS [4] - Transient liver enzyme elevations were more frequent in the fenebrutinib group (13.3% vs 2.9% for OCREVUS), but all cases resolved after discontinuation [4] Group 4: Future Developments - Roche plans to submit regulatory applications for fenebrutinib in both PPMS and relapsing multiple sclerosis (RMS) following the readout of the second pivotal RMS study, FENhance 1, expected in mid-2026 [5][6]

Core Insights - Roche announced that fenebrutinib, an investigational BTK inhibitor, met its primary endpoint of non-inferiority compared to OCREVUS in reducing disability progression in patients with primary progressive multiple sclerosis (PPMS), showing a 12% reduction in risk of disability progression [1][5] - The treatment effect was consistent across patient subgroups and observed as early as 24 weeks, particularly benefiting upper limb function [3][5] Study Details - The FENtrepid study was a Phase III multicenter, randomized, double-blind trial involving 985 adult patients with PPMS, comparing daily oral fenebrutinib to intravenous OCREVUS for at least 120 weeks [7] - The primary endpoint was the time to onset of 12-week composite confirmed disability progression (cCDP12), which included measures of functional disability, walking speed, and upper limb function [8] Treatment Efficacy - Fenebrutinib demonstrated a 26% reduction in the risk of worsening upper limb function compared to OCREVUS [2] - A post-hoc analysis indicated fenebrutinib was superior to OCREVUS on a composite endpoint including two components of cCDP12, with a 22% reduction in risk [3] Safety Profile - Adverse events in the fenebrutinib group were comparable to OCREVUS, with infections occurring in 67.0% of patients on fenebrutinib versus 70.9% on OCREVUS [4] - Transient liver enzyme elevations were more common in the fenebrutinib group (13.3% vs 2.9% for OCREVUS), but all cases resolved after discontinuation of the drug [4] Future Developments - Roche plans to submit regulatory applications for fenebrutinib in both PPMS and relapsing multiple sclerosis (RMS) following the readout of the second pivotal RMS study, FENhance 1, expected in mid-2026 [5][6]